Literature DB >> 9744718

US and UK health economics: two disciplines separated by a common language?

J P Newhouse1.   

Abstract

Victor Fuchs recently conducted two survey questionnaires of American health economists, showing substantial consensus among them on positive questions and much less consensus on policy questions. I attempted to replicate Fuch's surveys for members of the HESG. I dropped some items that were specific to an American context and added some new questions. Overall there was less agreement on positive questions and more on policy questions than among the US economists. Alan Williams' 1985 article 'Economics of Coronary Artery Bypass Grafting' was deemed the most influential by a British author on health economics as a discipline and British health policy.

Mesh:

Year:  1998        PMID: 9744718     DOI: 10.1002/hec.4730070907

Source DB:  PubMed          Journal:  Health Econ        ISSN: 1057-9230            Impact factor:   3.046


  8 in total

Review 1.  A new perspective on economic analysis in health care? A critical review of 'The Economics of Health Reconsidered' by Tom Rice.

Authors:  S Jan
Journal:  Health Care Anal       Date:  1999

Review 2.  Applications of economic models in healthcare: the introduction of pioglitazone in Sweden.

Authors:  Freddie Henriksson
Journal:  Pharmacoeconomics       Date:  2002       Impact factor: 4.981

3.  The case for stratified cost-effectiveness analysis by baseline health-related QOL: theory and sensitivity analysis.

Authors:  Joseph Schaafsma
Journal:  Pharmacoeconomics       Date:  2005       Impact factor: 4.981

4.  Cost effectiveness of raloxifene in the treatment of osteoporosis in Sweden: an economic evaluation based on the MORE study.

Authors:  Fredrik Borgström; Olof Johnell; John A Kanis; Anders Oden; David Sykes; Bengt Jönsson
Journal:  Pharmacoeconomics       Date:  2004       Impact factor: 4.981

5.  Residual effect after oral bisphosphonate treatment and healthy adherer effects--the Swedish Adherence Register Analysis (SARA).

Authors:  O Ström; E Landfeldt; G Garellick
Journal:  Osteoporos Int       Date:  2014-10-09       Impact factor: 4.507

6.  Cost effectiveness of bisoprolol in the treatment of chronic congestive heart failure in Sweden: analysis using data from the Cardiac Insufficiency Bisoprolol Study II trial.

Authors:  M Ekman; N Zethraeus; B Jönsson
Journal:  Pharmacoeconomics       Date:  2001       Impact factor: 4.981

7.  An economic model of long-term use of celecoxib in patients with osteoarthritis.

Authors:  Michael Loyd; Dale Rublee; Philip Jacobs
Journal:  BMC Gastroenterol       Date:  2007-07-04       Impact factor: 3.067

8.  The cost-utility of maintenance treatment with venlafaxine in patients with recurrent major depressive disorder.

Authors:  P Sobocki; M Ekman; A Ovanfors; R Khandker; B Jönsson
Journal:  Int J Clin Pract       Date:  2008-02-15       Impact factor: 2.503

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.